Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.54 |
| ▸ | TNF | P01375 | 2/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.54 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | F2R | P25116 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14891383 | 0.87 | HTT (0.63) | HTTCYP1A2CYP2D6POLBCXCR4 | |
| SCHEMBL21311239 | 0.84 | HTT (0.59) | HTTCYP1A2CYP2D6POLBCXCR4 | |
| SCHEMBL979423 | 0.83 | HTT (0.62) | HTTCYP1A2CYP2D6POLBCXCR4 | |
| SCHEMBL1707586 | 0.83 | HTT (0.62) | HTTCYP1A2CYP2D6POLBCXCR4 | |
| SCHEMBL1979530 | 0.82 | HTT (0.56) | HTTCYP1A2CYP2D6POLBCXCR4 | |
| SCHEMBL13111951 | 0.81 | TNF (0.60) | HTTTNFTP53 | |
| SCHEMBL1992429 | 0.80 | CYP1A2 (1.00) | HTTCYP1A2CYP2D6POLBCXCR4 | |
| SCHEMBL6199065 | 0.80 | CXCR4 (0.85) | HTTCYP1A2CYP2D6POLBCXCR4 | |
| SCHEMBL13071435 | 0.79 | MEN1 (0.47) | HTTCYP1A2CYP2D6POLBCXCR4 | |
| SCHEMBL1537674 | 0.79 | SMN1; SMN2 (0.55) | HTTCYP1A2CYP2D6POLBNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | HTT 4547/4885CYP1A2 3740/4885CYP2D6 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.